Therefore, targeting the VEGF pathway in MS seems a promising approach to treat the early, inflammation-driven phase of MS (RRMS) rather than the chronic-progressive phase of the disease (SPMS). The gene discussed is VEGFA; the disease is myeloid sarcoma.